Extension Study to Evaluate NBI-827104 in Pediatric Participants With Epileptic Encephalopathy With Continuous Spike-and-Wave During Sleep

Stopped early · Phase 2

Conditions studied: Epileptic Encephalopathy, Continuous Spike and Wave During Sleep

In brief

The primary objective for this study is to evaluate the long-term safety and tolerability of NBI-827104 in pediatric participants with epileptic encephalopathy with continuous spike-and-wave during sleep (EECSWS).

Key facts

Study ID

NCT05301894

Run by

Neurocrine Biosciences

People needed

19

Starts

2022-06-07

Expected to finish

2025-01-27

Last updated by the study team

2026-02-13

Who can join

Age: 4 and older, up to 12. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Neurocrine Clinical Site — Orange, California, United States
• Neurocrine Clinical Site — Aurora, Colorado, United States
• Neurocrine Clinical Site — Washington D.C., District of Columbia, United States
• Neurocrine Clinical Site — Miami, Florida, United States
• Neurocrine Clinical Site — Rochester, Minnesota, United States
• Neurocrine Clinical Site — Durham, North Carolina, United States
• Neurocrine Clinical Site — Cleveland, Ohio, United States
• Neurocrine Clinical Site — Dianalund, Denmark
• Neurocrine Clinical Site — Barcelona, Spain
• Neurocrine Clinical Site — Madrid, Spain
• Neurocrine Clinical Site — Zurich, Switzerland
• Neurocrine Clinical Site — London, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.